Therapy of advanced gastric carcinoma. The Georgetown-Lombardi cancer center experience

J. Treat; C. Falchuk; P. V. Woolley; J. D. Ahlgren; J. R. Neefe; F. P. Smith; J. S. Macdonald; P. S. Schein

doi:10.1097/00000421-198904000-00015

Therapy of advanced gastric carcinoma. The Georgetown-Lombardi cancer center experience

J. Treat, C. Falchuk, P. V. Woolley, J. D. Ahlgren, J. R. Neefe, F. P. Smith, J. S. Macdonald, P. S. Schein

Drexel University

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Gastric carcinoma, despite a decreasing incidence in the United States over the past 40 years, is the seventh most common cause of cancer death in this country and remains a significant worldwide problem. The 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin (FAM) chemotherapy regimen, which was initially reported by Georgetown in 1979, has become a standard for advanced gastric carcinoma with response in the 40% range. The FAM regimen as well as subsequent trials conducted at Georgetown and our current approach to management of this tumor are discussed. Despite a decade of intensive clinical research, we have not identified a modification or innovation that is superior to the original FAM.

Original language	English
Pages (from-to)	162-168
Number of pages	7
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	12
Issue number	2
DOIs	https://doi.org/10.1097/00000421-198904000-00015
State	Published - 1989

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/00000421-198904000-00015

Cite this

@article{0c866580ad18435ca43699877e3845a4,

title = "Therapy of advanced gastric carcinoma. The Georgetown-Lombardi cancer center experience",

abstract = "Gastric carcinoma, despite a decreasing incidence in the United States over the past 40 years, is the seventh most common cause of cancer death in this country and remains a significant worldwide problem. The 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin (FAM) chemotherapy regimen, which was initially reported by Georgetown in 1979, has become a standard for advanced gastric carcinoma with response in the 40% range. The FAM regimen as well as subsequent trials conducted at Georgetown and our current approach to management of this tumor are discussed. Despite a decade of intensive clinical research, we have not identified a modification or innovation that is superior to the original FAM.",

author = "J. Treat and C. Falchuk and Woolley, {P. V.} and Ahlgren, {J. D.} and Neefe, {J. R.} and Smith, {F. P.} and Macdonald, {J. S.} and Schein, {P. S.}",

year = "1989",

doi = "10.1097/00000421-198904000-00015",

language = "English",

volume = "12",

pages = "162--168",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "2",

}

TY - JOUR

T1 - Therapy of advanced gastric carcinoma. The Georgetown-Lombardi cancer center experience

AU - Treat, J.

AU - Falchuk, C.

AU - Woolley, P. V.

AU - Ahlgren, J. D.

AU - Neefe, J. R.

AU - Smith, F. P.

AU - Macdonald, J. S.

AU - Schein, P. S.

PY - 1989

Y1 - 1989

N2 - Gastric carcinoma, despite a decreasing incidence in the United States over the past 40 years, is the seventh most common cause of cancer death in this country and remains a significant worldwide problem. The 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin (FAM) chemotherapy regimen, which was initially reported by Georgetown in 1979, has become a standard for advanced gastric carcinoma with response in the 40% range. The FAM regimen as well as subsequent trials conducted at Georgetown and our current approach to management of this tumor are discussed. Despite a decade of intensive clinical research, we have not identified a modification or innovation that is superior to the original FAM.

AB - Gastric carcinoma, despite a decreasing incidence in the United States over the past 40 years, is the seventh most common cause of cancer death in this country and remains a significant worldwide problem. The 5-fluorouracil, Adriamycin (doxorubicin), and mitomycin (FAM) chemotherapy regimen, which was initially reported by Georgetown in 1979, has become a standard for advanced gastric carcinoma with response in the 40% range. The FAM regimen as well as subsequent trials conducted at Georgetown and our current approach to management of this tumor are discussed. Despite a decade of intensive clinical research, we have not identified a modification or innovation that is superior to the original FAM.

UR - http://www.scopus.com/inward/record.url?scp=0024510468&partnerID=8YFLogxK

U2 - 10.1097/00000421-198904000-00015

DO - 10.1097/00000421-198904000-00015

M3 - Article

C2 - 2523188

AN - SCOPUS:0024510468

SN - 0277-3732

VL - 12

SP - 162

EP - 168

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 2

ER -

Therapy of advanced gastric carcinoma. The Georgetown-Lombardi cancer center experience

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this